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Edited by Michael R. BubbAbstract Apigenin, a plant-derived ﬂavone, is a potent inhibitor
of cell proliferation and angiogenesis, but the mechanisms
leading to the pathological anti-angiogenic eﬀects of apigenin
are still unclear. In this study, we found that apigenin inhibited
the hypoxia-induced expression of vascular endothelial growth
factor (VEGF) mRNA in human umbilical artery endothelial
cells. Apigenin also suppressed the expression of erythropoietin
mRNA, which is a typical hypoxia-inducible gene, via the
degradation of hypoxia-inducible factor 1 (HIF-1) a. We
investigated the eﬀect of apigenin on the interaction of HIF-1a
with heat shock protein 90 (Hsp90), which is reported to be
important for the stabilization of HIF-1a, and found that VEGF
expression was inhibited via degradation of HIF-1a through
interference with the function of Hsp90.
 2004 Published by Elsevier B.V. on behalf of the Federation of
European Biochemical Societies.
Keywords: Apigenin; Angiogenesis; Vascular endothelial
growth factor; Hypoxia; Hypoxia-inducible factor;
Heat shock protein 901. Introduction
Several polyphenolic compounds are recognized as cancer
chemopreventive agents. Flavonoids are especially well known
to suppress tumor cell growth via cell-cycle arrest and by the
induction of apoptosis in several tumor cell lines [1–5].
Moreover, ﬂavonoids inhibit endothelial cell proliferation and
angiogenesis in vitro, the latter is endothelial cell cultures on
collagen gels [6,7]. Angiogenesis is essential for the growth,
progression, and metastasis of solid tumors [8]. Apigenin, a
member of the ﬂavone family that is present at high levels in* Corresponding author. Fax: +81-6-6645-3917.
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Abbreviations: VEGF, vascular endothelial growth factor; HIF-1,
hypoxia-inducible factor 1; EPO, erythropoietin; pVHL, von Hippel–
Lindau protein; Hsp90, heat shock protein 90; HRE, hypoxia response
element; ARNT, aryl hydrocarbon receptor nuclear translocator;
ODD, oxygen-dependent degradation; NPR, NADPH-P450 reductase;
HUA-EC, human umbilical artery endothelial cells; RT-PCR, reverse-
transcription PCR; SDS–PAGE, SDS–polyacrylamide gel electropho-
resis; PAS, Per-ARNT-Sim; bHLH, basic helix loop helix
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doi:10.1016/j.febslet.2004.08.036many vegetables, has been found to inhibit ornithine
decarboxylase and chemically induced skin tumorigenesis
[9]. However, the mechanism by which apigenin suppresses
angiogenesis has not been elucidated.
A prime regulator for angiogenesis is believed to be vas-
cular endothelial growth factor (VEGF) and low oxygen
tension dramatically induces the expression of this major
angiogenic factor [10]. Transcriptional upregulation of
VEGF has been implicated in the induction of genes; the
induction is mediated by the speciﬁc binding of hypoxia-
inducible factor 1 (HIF-1) to the hypoxia response element
(HRE) [10–12]. The transcription factor HIF-1 is a hetero-
dimer composed of HIF-1a and aryl hydrocarbon receptor
nuclear translocator (ARNT), also known as HIF-1b [13,14].
Although the ARNT protein is readily found in cells, HIF-
1a is virtually undetectable in normal conditions. When cells
are subjected to hypoxic conditions, the protein levels of the
HIF-1a subunit increase rapidly. The existence of HIF-1
suggests that in the presence of oxygen, HIF-1a is regulated
by two separate mechanisms: one involving prolyl hydrox-
ylase, which initiates the degradation of HIF-1a, and an-
other involving asparagine hydroxylase, which inactivates
the C-terminal transactivation domain of HIF-1a [15]. Un-
der normoxic conditions, the proteasome-dependent degra-
dation of HIF-1a is mediated by prolyl hydroxylation,
which permits the binding of the von Hippel–Lindau protein
(pVHL), a component of the E3 ubiquitin ligase [16,17].
Under hypoxic conditions, prolyl hydroxylation of HIF-1a is
blocked and the transcription factor HIF-1 is stabilized.
Detailed study of HIF-1a protein revealed a 200-amino-acid
sequence called the oxygen-dependent degradation (ODD)
domain [18]. This domain is responsible for the degradation
of HIF-1a in the presence of oxygen. pVHL mediates the
ubiquitination and degradation of HIF-1a by binding to the
ODD domain under normoxic conditions. It has been well
documented that cobalt, a transition metal, mimics the ef-
fects of hypoxia by stabilizing HIF-1a [19]. However, the
biochemical mechanisms underlying this stabilization diﬀer
from those underlying the stabilization induced by hypoxia.
We have already reported that HIF-1a signal transduction
during hypoxia was mediated by NADPH-P450 reductase
(NPR) [20]. But NPR has little or no eﬀect on erythropoi-
etin (EPO) mRNA induction by cobalt. A recent study
demonstrated that cobalt inhibits HIF–pVHL interaction
even after hydroxylation of the proline residue [21], leading
to a rapid accumulation of HIF-1a protein.ation of European Biochemical Societies.
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angiogenic eﬀect of apigenin on tumor cells is caused by a
reduction in the expression of VEGF, which is regulated
by HIF-1 under hypoxic conditions. Moreover, we inves-
tigated a mechanism by which apigenin induces degrada-
tion of HIF-1a, independent of the ubiquitination of
pVHL.Fig. 1. Expression of VEGF mRNA in HUA-EC. HUA-EC were ex-
posed to 5% O2, 5% CO2 and 90% N2 for 6 h in the presence or ab-
sence of 20 lM apigenin. VEGF mRNA expression was analyzed by
RT-PCR.2. Materials and methods
2.1. Materials
Dulbecco’s modiﬁed Eagle’s medium (DMEM), EGM-2 medium,
fetal calf serum, and N-CBZ-Leu-Leu-Norvalinal (proteasome in-
hibitor) were purchased from Sigma Chemical Co. (St. Louis,
MO). Isogen was obtained from Nippon Gene (Toyama, Japan).
An RNA PCR Kit (AMV) Ver. 2.1 was purchased from Takara
(Shiga, Japan). Anti-human HIF-1a IgG and anti-human ARNT
IgG were obtained from Novus (Littleton, CO) and Abcam
(Cambridgeshire, UK), respectively. Anti-human heat shock pro-
tein 90 (Hsp90) IgG was purchased from BD Biosciences (San
Jose, CA). Protein G–Sepharose 4 Faster Flow was supplied by
Amersham Biosciences Corp. (Piscataway, NJ). Nitrocellulose
membrane and 4-chloro-1-naphthol were purchased from Bio-Rad
Laboratories (Hercules, CA). The Vectastain ABC kit (a biotin/
avidin system) was obtained from Vector Laboratories (Burlin-
game, CA).
2.2. Cell culture
The human hepatoma cell line Hep3B was obtained from the Cell
Resource Center for Biomedical Research at the Institute of Devel-
opment, Aging and Cancer, Tohoku University (Miyagi, Japan). Hu-
man umbilical artery endothelial cells (HUA-EC) were obtained from
Cambrex Bioscience Bio-Whittaker (Walkersville, MD). The Hep3B
cells were maintained in DMEM containing 10% fetal calf serum and
the HUA-EC in EGM-2 containing 10% fetal calf serum. To stimulate
hypoxia, the cells were incubated in 5% O2, 5% CO2 and 90% N2
balanced with a modulator incubator chamber (Napco 7101, Win-
chester, VA) or in a sealed 2.5-L box with an Anero Pack (oxygen
absorber) for cells (Mitsubishi Gas Chemical Company, Inc., Tokyo,
Japan).
2.3. Isolation of RNA and reverse-transcription PCR (RT-PCR)
With the use of Isogen, total RNA was extracted from Hep3B
cells and from HUA-EC. The total RNA was transcribed into
cDNA using the RNA PCR Kit according to the manufacturer’s
protocol. PCR with 10 pmol of each primer, 1.5 U of Ampli Taq,
and 100 ng of cDNA was performed for 10 min at 94 C and
then 35 cycles of 1 min at 94 C, 1 min at 56 C and 2.5 min
at 72 C. The PCR primers for EPO [22] were 50-
GCCAGAGGAACTGACCAGAG-30 (sense) and 50-TTCTTCA-
GGTCATCCTATCC-30 (antisense), while the PCR primers for
VEGF [23] were 50-TTCATGGATGTCTATCAGCG-30 (sense) and
50-CATCTCTCCTATGTGCTGGC-30 (antisense). The oligonucleo-
tide sequences of the reaction products were conﬁrmed by
sequencing.
2.4. Western blotting and immunoprecipitation
Cells at 80% conﬂuence were lysed in 20 mM Tris–HCl buﬀer (pH
8.0) containing 0.1% Tween 20, 10% glycerol, 5 mM MgCl2, 300
mM KCl, and 20 lM N-CBZ-Leu-Leu-Norvalinal. Cell lysates were
divided into two and incubated with 2.8 lg of anti-HIF-1a IgG at 4
C. Apigenin (100 lM) was added together with anti-HIF-1a IgG.
After 2 h, 60 lL of protein G (10% vol/vol in lysis buﬀer) was
added to each incubation mixture, and the incubation continued for
another 2 h. Samples were washed twice by lysis buﬀer and protein
G was removed by centrifugation. Samples were analyzed by SDS–
polyacrylamide gel electrophoresis (SDS–PAGE) with 7.5%
polyacrylamide gel. Using a previously described method [24], we
performed immunoblotting with anti-ARNT IgG, anti-Hsp90 IgG,
or antibodies against HIF-1a that were prepared in our laboratory
[20]. Each protein was visualized using the ABC kit and 4-chloro-1-
naphthol.3. Results
3.1. Eﬀect of apigenin on VEGF expression under hypoxia
HUA-EC were used to investigate the inhibitory eﬀect of
apigenin on VEGF expression (Fig. 1). When HUA-EC were
exposed to 5% O2 for 6 h, VEGF mRNA expression increased
markedly. However, VEGF mRNA disappeared completely
when apigenin (20 lM) was added to the culture medium.
These results show that the ﬂavone apigenin inhibited VEGF
mRNA expression under hypoxic conditions.
3.2. Eﬀect of apigenin on EPO expression during hypoxia
To examine whether or not apigenin inhibits the expression
of EPO mRNA induced by hypoxia, we used human hepato-
cyte (Hep3B) cells and analyzed EPO mRNA expression by
RT-PCR. The Hep3B cells were exposed to 5% O2 for 3 h and
then the expression of EPO mRNA was observed under hyp-
oxic conditions (Fig. 2A). Apigenin dose-dependently reduced
the expression. As HIF-1 was the transcription factor of the
EPO gene during hypoxia, we studied the levels of HIF-1a and
ARNT in Hep3B cells under hypoxic conditions by Western
blotting (Fig. 2B). Although no immunoreactive band for
HIF-1a was observed under normoxic conditions in Hep3B
cells, HIF-1a was clearly expressed during hypoxia. When
apigenin (100 lM) was added to the culture medium, the ex-
pression of HIF-1a was reduced. On the other hand, the levels
of ARNT, a subunit of HIF-1, were not at all aﬀected by
treatment with apigenin.
3.3. Eﬀect of apigenin on EPO expression induced by cobalt
Cobalt is known to inhibit the interaction between HIF-1a
and pVHL directly and thereby prevent the degradation of
HIF-1a [21]. To examine whether or not apigenin inhibits the
cobalt-induced stabilization of HIF-1a, Hep3B cells were
treated with apigenin in the presence of cobalt (Fig. 3A).
Apigenin inhibited the expression of EPO mRNA induced by
cobalt. Moreover, we tested the eﬀect of apigenin on the levels
of HIF-1a in Hep3B cells treated with cobalt (Fig. 3B). HIF-1a
expression increased on treatment with cobalt, whereas it ap-
parently decreased when apigenin (100 lM) was added to the
culture medium. These results indicate that apigenin inhibits
the stabilization of HIF-1a in the presence of cobalt. The
presence of apigenin did not change the ARNT levels. When
apigenin was present, HIF-1a was degraded under hypoxic
conditions or in the presence of cobalt ion under normoxic
conditions, suggesting that apigenin degraded HIF-1a via a
pVHL-independent pathway.
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hypoxia
Using geldanamycin, a speciﬁc inhibitor of Hsp90, Minet
et al. [25] demonstrated that Hsp90 was essential for stabilizing
HIF-1. In addition, HIF-1a belongs to the Per-ARNT-Sim
(PAS)-basic helix loop helix (bHLH) family and interacts with
Hsp90 [25,26]. We hypothesized that the degradation of HIF-
1a by apigenin correlates with the interaction between HIF-1a
and Hsp90. We prepared cell lysates from Hep3B under con-
ditions of hypoxia in the absence of apigenin. Apigenin was
added to the lysates together with anti-HIF-1a IgG and then
the complex anti-HIF-1a IgG was collected using protein G.
The samples were analyzed by SDS–PAGE with 7.5% poly-
acrylamide gel. The antibody against HIF-1a could pull down
Hsp90 protein, indicating that Hsp90 is associated with HIF-1a
(Fig. 4). When apigenin was added to the cell lysates together
with the antibody, the band of Hsp90 disappeared, indicating
that apigenin inhibited the interaction of HIF-1a with Hsp90.
Geldanamycin also reduced the levels of EPOmRNA inHep3B
cells under hypoxic conditions (data not shown).4. Discussion
Dietary factors contribute to about one-third of potentially
preventable cancers, and the preventive eﬀects of plant-based
diets on tumorigenesis and other chronic diseases have been
well documented [27]. Several cancers, including breast cancer,
have a lower incidence in Asia than in Western countries. This
has been attributed to the Asian dietary regimen, which is
typically rich in ﬂavonoid-containing plants. Researchers have
identiﬁed the isoﬂavonoid genistein as a potent inhibitor of
angiogenesis in vitro [6,7]. A recent study demonstrated thatFig. 2. Expression of EPO mRNA and HIF-1a in Hep3B cells under hypoxic
N2 for 3 h in the presence or absence of 20, 50, or 100 lM apigenin. EPO mR
Actin mRNA) under hypoxia was 100%. Values are given as means S.D. for
CO2 and 90% N2 for 3 hours in the presence or absence of 100 lM apigenin.
analyzed by SDS–PAGE with 7.5% poly-acrylamide gel, and then were imm
were analyzed by SDS–PAGE with 7.5% polyacrylamide gel and immunobl
antibody and HIF-1a was detected with 4-chloro-1-naphthol.the anti-angiogenic eﬀect of genistein was due to inhibition of
HIF-1, an important regulator of VEGF gene homeostasis
particularly under low-oxygen conditions [28]. The ﬂavone
apigenin has also been proposed as an antitumor agent [29].
However, the molecular mechanisms involved in the anti-an-
giogenic eﬀects of apigenin are not well understood. This study
investigated the anti-angiogenic eﬀects of apigenin on cells
under hypoxic conditions. We observed that apigenin sup-
pressed the expression of both VEGF mRNA and EPO
mRNA induced by hypoxia in HUA-EC and in Hep3B cells.
Apigenin proved more eﬀective against the expression of
VEGF mRNA and EPO mRNA than genistein (data not
shown). In this study, we found that apigenin caused the
degradation of HIF-1a but not of ARNT. Given that geni-
stein has been reported to inhibit HIF-1 DNA-binding activity
[28], apigenin and genistein may have diﬀerent angiogenic
mechanisms.
Apigenin inhibited the mRNA expression of EPO induced
by cobalt, which mimics hypoxia; it also inhibited the stabil-
ization of HIF-1a induced by cobalt. Because the mechanism
underlying the stabilization of HIF-1a during hypoxia is
known to diﬀer from that induced by cobalt, we speculate that
the degradation of HIF-1a by apigenin is independent of the
ubiquitination by pVHL. As geldanamycin reduced the ex-
pression of EPO mRNA in Hep3B cells under hypoxic con-
ditions (data not shown), we examined the eﬀect of apigenin on
the interaction with HIF-1a of the chaperone protein Hsp90,
which associates with HIF-1a to stabilize an activated form of
HIF-1 during hypoxia [25,30]. Through immunoprecipitation
experiments, we found that apigenin disturbed the binding of
Hsp90 to HIF-1a. These results indicate that apigenin dimin-
ishes the hypoxia-induced interaction of HIF-1a with Hsp90 to
release HIF-1a, which in turn undergoes degradation.conditions. (A) Hep3B cells were exposed to 5% O2, 5% CO2 and 90%
NA expression was analyzed by RT-PCR. The ratio (EPO mRNA/b-
four separate experiments. (B) Hep3B cells were exposed to 5% O2, 5%
Whole cell lysates were immunoprecipitated with anti-HIF-1a IgG and
unoblotted with antibodies against HIF-1a. Whole cell lysates (50 lg)
otted with anti-ARNT IgG. An ABC kit was used for the secondary
Fig. 3. Expression of EPO mRNA and HIF-1a in Hep3B cells treated with cobalt. Hep3B cells were exposed to 100 lM cobalt for 3 h in the presence
or absence of 100 lM apigenin. (A) EPO mRNA expression was analyzed by RT-PCR. The ratio (EPO mRNA/b-Actin mRNA) under hypoxia was
100%. Values are given as means S.D. for four separate experiments. (B) Whole cell lysates were analyzed by SDS–PAGE with 7.5% poly-ac-
rylamide gel and immunoblotted with antibodies against HIF-1a (1:100). An ABC kit was used for the secondary antibody and HIF-1a was detected
with 4-chloro-1-naphthol.
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have an inhibitory eﬀect on the expression of EPO mRNA
induced by hypoxia. We found that kaempferol and myricetin
have an inhibitory eﬀect on the expression under hypoxic
conditions, but catechin and epicatechin do not (data not
shown). Wilson et al. [31] demonstrated that the ﬂavonoid
quercetin stabilizes HIF-1a and induces the expression of
VEGF mRNA under normoxic conditions. Moreover, it has
been proposed that quercetin regulates the response to hypoxia
by inhibiting the activity of HIF hydroxylase, a member of theFig. 4. Interaction of HIF-1a and Hsp90 proteins in the presence of
apigenin. Hep3B cells were exposed to 5% O2, 5% CO2 and 90% N2 for
3 h. Apigenin (100 lM) was added to whole cell lysates. The lysates
were immunoprecipitated with anti-HIF-1a IgG and analyzed by
SDS–PAGE with 7.5% polyacrylamide gel and immunoblotted with
antibodies against HIF-1a (1:100) (A) and anti-Hsp90 IgG (B).Fe(II), 2-oxoglutarate-dependent dioxygenase family, because
quercetin is a good iron chelator [32].
In this study, we found that apigenin reduced HIF-1a levels
by interfering with the binding of HIF-1a to Hsp90, leading to
a suppression of EPO mRNA transcription. The angiogenesis
frequently observed in tumors would be suppressed by apige-
nin via a reduction of VEGF mRNA expression. Since it may
suppress a number of genes induced by HIF-1a, it is likely that
apigenin could be a potent inhibitor of angiogenesis. Our re-
sults clearly show that apigenin is potentially an important
chemical for controlling HIF-1a levels.
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